Inhibiting Human Parainfluenza Virus Infection by Preactivating the Cell Entry Mechanism.

Animals Antibodies, Monoclonal / immunology Antibodies, Viral / immunology Antiviral Agents / chemical synthesis Cell Line Chlorocebus aethiops HN Protein / metabolism Humans Parainfluenza Virus 3, Human / drug effects Protein Binding Protein Conformation Viral Fusion Proteins / chemistry Viral Plaque Assay Virus Internalization / drug effects
antiviral conformational antibody fusion activation paramyxovirus viral fusion viral glycoprotein antibody

Journal

mBio
ISSN: 2150-7511
Titre abrégé: mBio
Pays: United States
ID NLM: 101519231

Informations de publication

Date de publication:
19 02 2019
Historique:
entrez: 21 2 2019
pubmed: 21 2 2019
medline: 26 3 2019
Statut: epublish

Résumé

Paramyxoviruses, specifically, the childhood pathogen human parainfluenza virus type 3, are internalized into host cells following fusion between the viral and target cell membranes. The receptor binding protein, hemagglutinin (HA)-neuraminidase (HN), and the fusion protein (F) facilitate viral fusion and entry into the cell through a coordinated process involving HN activation by receptor binding, which triggers conformational changes in the F protein to activate it to reach its fusion-competent state. Interfering with this process through premature activation of the F protein has been shown to be an effective antiviral strategy

Identifiants

DOI: 10.1128/mBio.02900-18 PMID: 30782664 PMC: PMC6381285
pubmed: 30782664
pii: mBio.02900-18
doi: 10.1128/mBio.02900-18
pmc: PMC6381285
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antibodies, Viral 0
Antiviral Agents 0
HN Protein 0
Viral Fusion Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI031971
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI114736
Pays : United States

Informations de copyright

Copyright © 2019 Bottom-Tanzer et al.

Références

J Virol. 2014 Nov;88(22):13495-502
pubmed: 25210187
J Virol. 2011 Dec;85(24):12867-80
pubmed: 21976650
Biomaterials. 2012 Jan;33(3):962-9
pubmed: 22018388
J Virol. 2006 Feb;80(3):1204-13
pubmed: 16414997
J Virol. 2007 Sep;81(17):9152-61
pubmed: 17567695
PLoS Pathog. 2016 Sep 09;12(9):e1005859
pubmed: 27611367
J Mol Biol. 2004 Jan 30;335(5):1343-57
pubmed: 14729348
PLoS Pathog. 2010 Oct 28;6(10):e1001168
pubmed: 21060819
BMC Infect Dis. 2002 Apr 30;2:6
pubmed: 11983022
Nat Chem Biol. 2016 Feb;12(2):87-93
pubmed: 26641933
N Engl J Med. 2014 Aug 21;371(8):711-22
pubmed: 25140957
Curr Opin Infect Dis. 2018 Dec;31(6):520-526
pubmed: 30299356
N Engl J Med. 2009 Mar 5;360(10):953-6
pubmed: 19258250
J Infect Dis. 2010 Jul 15;202(2):234-41
pubmed: 20533871
J Virol. 1986 Aug;59(2):377-83
pubmed: 3016304
Lancet. 2010 Jun 5;375(9730):1969-87
pubmed: 20466419
Biochemistry. 1993 Mar 30;32(12):2967-78
pubmed: 8457561
mBio. 2016 Mar 15;7(2):e00235
pubmed: 26980833
J Cell Biol. 2003 Oct 27;163(2):363-74
pubmed: 14581458
mBio. 2012 Jun 05;3(3):
pubmed: 22669629
Nat Commun. 2017 Nov 16;8(1):1528
pubmed: 29142300
Virology. 1999 Dec 5;265(1):57-65
pubmed: 10603317
J Virol. 2012 Dec;86(23):12838-48
pubmed: 22993149
J Virol. 2002 Jun;76(11):5654-66
pubmed: 11991994
Respir Res. 2007 May 17;8:38
pubmed: 17509128
J Virol Methods. 2015 Nov;224:1-8
pubmed: 26275682
J Biol Chem. 2011 Nov 4;286(44):37945-54
pubmed: 21799008
J Virol. 2014 Mar;88(5):2951-66
pubmed: 24371057
J Biol Chem. 2012 Jan 2;287(1):778-93
pubmed: 22110138
J Clin Invest. 2005 Jul;115(7):1688-98
pubmed: 16007245
J Virol. 2005 Jan;79(2):1113-24
pubmed: 15613339
Pediatr Res. 1990 Jun;27(6 Suppl):S39-43
pubmed: 2113272
Nature. 2006 Jan 5;439(7072):38-44
pubmed: 16397490
Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14306-13
pubmed: 9405608
Proc Natl Acad Sci U S A. 2018 Apr 17;115(16):4240-4245
pubmed: 29610325
Biochemistry. 1999 Apr 27;38(17):5378-85
pubmed: 10220324
J Virol. 2004 Dec;78(24):13911-9
pubmed: 15564499
mBio. 2015 Feb 10;6(1):
pubmed: 25670774
Nat Rev Genet. 2008 Apr;9(4):267-76
pubmed: 18319742
Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17736-41
pubmed: 19004788
Bull World Health Organ. 2008 May;86(5):408-16
pubmed: 18545744
Exp Ther Med. 2010 Mar;1(2):251-256
pubmed: 22993536
Curr Opin Virol. 2017 Jun;24:60-69
pubmed: 28527859
mBio. 2018 Jul 3;9(4):
pubmed: 29970463
J Virol. 2009 Jul;83(13):6900-8
pubmed: 19386708
mBio. 2013 Oct 22;4(5):e00803-13
pubmed: 24149514
J Virol. 2005 Feb;79(4):2383-92
pubmed: 15681439
J Virol. 2000 Dec;74(23):11108-14
pubmed: 11070006
Annu Rev Microbiol. 1997;51:151-78
pubmed: 9343347
J Virol. 2001 Aug;75(16):7481-8
pubmed: 11462020
J Virol. 1997 Nov;71(11):8808-20
pubmed: 9343241

Auteurs

S F Bottom-Tanzer (SF)

Department of Pediatrics, Columbia University Medical Center, New York, New York, USA.
Center for Host-Pathogen Interaction, Columbia University Medical Center, New York, New York, USA.

K Rybkina (K)

Department of Pediatrics, Columbia University Medical Center, New York, New York, USA.
Center for Host-Pathogen Interaction, Columbia University Medical Center, New York, New York, USA.

J N Bell (JN)

Department of Pediatrics, Columbia University Medical Center, New York, New York, USA.
Center for Host-Pathogen Interaction, Columbia University Medical Center, New York, New York, USA.

C A Alabi (CA)

Robert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, New York, USA.

C Mathieu (C)

Department of Pediatrics, Columbia University Medical Center, New York, New York, USA.
Center for Host-Pathogen Interaction, Columbia University Medical Center, New York, New York, USA.
CIRI, International Center for Infectiology Research, Immunobiology of Viral Infections Team, INSERM U1111, University Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Lyon, France.

M Lu (M)

Department of Microbiology, Biochemistry and Molecular Genetics, Rutgers Biomedical and Health Sciences, Public Health Research Institute, Newark, New Jersey, USA.

S Biswas (S)

Department of Pediatrics, Columbia University Medical Center, New York, New York, USA.
Center for Host-Pathogen Interaction, Columbia University Medical Center, New York, New York, USA.
Robert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, New York, USA.

M Vasquez (M)

Centro Nacional de Microbiología and CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.

M Porotto (M)

Department of Pediatrics, Columbia University Medical Center, New York, New York, USA.
Center for Host-Pathogen Interaction, Columbia University Medical Center, New York, New York, USA.
Department of Experimental Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.

J A Melero (JA)

Centro Nacional de Microbiología and CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.

V Más (V)

Centro Nacional de Microbiología and CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.

A Moscona (A)

Department of Pediatrics, Columbia University Medical Center, New York, New York, USA am939@cumc.columbia.edu.
Center for Host-Pathogen Interaction, Columbia University Medical Center, New York, New York, USA.
Department of Microbiology & Immunology, Columbia University Medical Center, New York, New York, USA.
Department of Physiology & Cellular Biophysics, Columbia University Medical Center, New York, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Inhibiting Human Parainfluenza Virus Infection...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Inhibiting Human Parainfluenza Virus Infection...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antiviraux › Inhibiting Human Parainfluenza Virus Infection...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiviraux › Inhibiting Human Parainfluenza Virus Infection...
questionsmedicales.fr › Cellules › Cellules cultivées › Lignée cellulaire › Inhibiting Human Parainfluenza Virus Infection...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Cercopithecidae › Cercopithecinae › Cercopithecus › Cercopithecus aethiops › Inhibiting Human Parainfluenza Virus Infection...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes viraux › Hémagglutinines virales › Protéine HN › Inhibiting Human Parainfluenza Virus Infection...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Inhibiting Human Parainfluenza Virus Infection...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN de polarité négative › Mononegavirales › Paramyxoviridae › Paramyxovirinae › Respirovirus › Virus parainfluenza humain de type 3 › Inhibiting Human Parainfluenza Virus Infection...
questionsmedicales.fr › Métabolisme › Liaison aux protéines › Inhibiting Human Parainfluenza Virus Infection...
questionsmedicales.fr › Phénomènes chimiques › Phénomènes biochimiques › Conformation moléculaire › Conformation des protéines › Inhibiting Human Parainfluenza Virus Infection...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines virales › Protéines virales structurales › Protéines de l'enveloppe virale › Protéines de fusion virale › Inhibiting Human Parainfluenza Virus Infection...
questionsmedicales.fr › Techniques d'investigation › Techniques de laboratoire clinique › Techniques microbiologiques › Culture virale › Méthode des plages virales › Inhibiting Human Parainfluenza Virus Infection...
questionsmedicales.fr › Phénomènes microbiologiques › Phénomènes physiologiques viraux › Pénétration virale › Inhibiting Human Parainfluenza Virus Infection...